f-star Biotechnology Research & Development Co.

Vienna-based f-star Biotechnology's platform allows it to enhance the functionality of antibodies by introducing additional binding sites. F-star is also investigating antibody fragments and what it calls "compressed" antibodies, or protein scaffolds with key antibody characteristics tacked on, but much smaller in size. These, it claims, may be easier to produce than full-sized antibodies, with better tissue penetration and potentially better efficacy.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip